Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice
Our results indicate that EDB can improve cognitive function and slow down AD progression, and it may serve as a potential agent for AD and other S100A9-related diseases.
Authors
- Shu Shu (ORCID: https://orcid.org/0000-0001-5229-3624)
- Siyi Xu (ORCID: https://orcid.org/0000-0002-5147-2644)
- Ming Hu (ORCID: https://orcid.org/0000-0002-2744-6294)
- Junqiu Jia
- Rui Mao (ORCID: https://orcid.org/0000-0002-1082-8755)
- Xiaolei Zhu (ORCID: https://orcid.org/0000-0003-2733-242X)
- Lei Ye (ORCID: https://orcid.org/0000-0003-4064-4460)
- Yun Xu
- Jiang Chen (ORCID: https://orcid.org/0000-0002-3385-7137)
- Xinyu Bao (ORCID: https://orcid.org/0009-0008-8230-349X)
- Min Sun
- Wenxuan Shao
Institutions
- Peking Union Medical College Hospital (CN)
- Nanjing Drum Tower Hospital (CN)
- Chinese Academy of Medical Sciences Dermatology Hospital (CN)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1186/s13195-025-01777-9
- Primary Topic
- S100 Proteins and Annexins
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China